Compare Stocks: AXLA, INM, LIMN, and BJDX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXLA Axcella Health	$0.40	$0.84	$0.34 ▼ $41.25	$1.18M	0.46	267,009 shs	N/A
BJDX Bluejay Diagnostics	$0.90 -1.0%	$1.34	$0.83 ▼ $16.68	$4.02M	0.89	6.14 million shs	11.27 million shs
INM InMed Pharmaceuticals	$1.38 -3.5%	$1.54	$0.58 ▼ $2.50	$4.57M	0.96	91,910 shs	111,847 shs
LIMN Liminatus Pharma	$4.23 -3.9%	$5.70	$4.23 ▼ $154.50	$4.28M	5.35	655,043 shs	38,621 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXLA Axcella Health	0.00%	0.00%	0.00%	0.00%	0.00%
BJDX Bluejay Diagnostics	0.00%	-1.20%	-3.15%	-57.94%	-83.58%
INM InMed Pharmaceuticals	0.00%	-5.48%	-8.00%	-12.10%	-38.67%
LIMN Liminatus Pharma	0.00%	-18.02%	-17.14%	-48.41%	-97.20%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXLA Axcella Health	$0.40	$0.84	$0.34 ▼ $41.25	$1.18M	0.46	267,009 shs	N/A
BJDX Bluejay Diagnostics	$0.90 -1.0%	$1.34	$0.83 ▼ $16.68	$4.02M	0.89	6.14 million shs	11.27 million shs
INM InMed Pharmaceuticals	$1.38 -3.5%	$1.54	$0.58 ▼ $2.50	$4.57M	0.96	91,910 shs	111,847 shs
LIMN Liminatus Pharma	$4.23 -3.9%	$5.70	$4.23 ▼ $154.50	$4.28M	5.35	655,043 shs	38,621 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXLA Axcella Health	0.00%	0.00%	0.00%	0.00%	0.00%
BJDX Bluejay Diagnostics	0.00%	-1.20%	-3.15%	-57.94%	-83.58%
INM InMed Pharmaceuticals	0.00%	-5.48%	-8.00%	-12.10%	-38.67%
LIMN Liminatus Pharma	0.00%	-18.02%	-17.14%	-48.41%	-97.20%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXLA Axcella Health	0.00	N/A	N/A	N/A
BJDX Bluejay Diagnostics	1.00	Sell	N/A	N/A
INM InMed Pharmaceuticals	1.00	Sell	N/A	N/A
LIMN Liminatus Pharma	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest AXLA, INM, LIMN, and BJDX Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/20/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	BJDX Bluejay Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	INM InMed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXLA Axcella Health	N/A	N/A	N/A	N/A	$1.42 per share	N/A
BJDX Bluejay Diagnostics	N/A	N/A	N/A	N/A	$2.11 per share	N/A
INM InMed Pharmaceuticals	$4.94M	0.93	N/A	N/A	$6.71 per share	0.21
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	$0.30 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXLA Axcella Health	-$81.19M	-$19.25	N/A	N/A	N/A	N/A	N/A	-259.91%	N/A
BJDX Bluejay Diagnostics	-$6.85M	-$7.11	N/A	N/A	N/A	N/A	-125.00%	-99.79%	11/13/2026 (Estimated)
INM InMed Pharmaceuticals	-$8.16M	-$2.89	N/A	N/A	N/A	-132.87%	-80.85%	-68.11%	9/23/2026 (Estimated)
LIMN Liminatus Pharma	-$10.21M	-$23.50	N/A	N/A	N/A	N/A	N/A	-256.58%	N/A

Latest AXLA, INM, LIMN, and BJDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/23/2026	Q4 2026	INM InMed Pharmaceuticals	-$94.4436	N/A	N/A	N/A	N/A	N/A
8/14/2026	Q2 2026	LIMN Liminatus Pharma	N/A	-$1.50	N/A	-$0.03	N/A	N/A
8/12/2026	Q2 2026	BJDX Bluejay Diagnostics	-$3,520.00	-$1.12	+$3,518.88	-$1.12	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXLA Axcella Health	N/A	N/A	N/A	N/A	N/A
BJDX Bluejay Diagnostics	N/A	N/A	N/A	N/A	N/A
INM InMed Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXLA Axcella Health	N/A	0.80	0.80
BJDX Bluejay Diagnostics	N/A	4.64	4.64
INM InMed Pharmaceuticals	N/A	3.12	3.12
LIMN Liminatus Pharma	N/A	1.12	1.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXLA Axcella Health	65.07%
BJDX Bluejay Diagnostics	18.47%
INM InMed Pharmaceuticals	20.12%
LIMN Liminatus Pharma	N/A

Insider Ownership

Company	Insider Ownership
AXLA Axcella Health	2.20%
BJDX Bluejay Diagnostics	6.10%
INM InMed Pharmaceuticals	0.85%
LIMN Liminatus Pharma	19.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXLA Axcella Health	11	2.95 million	2.88 million	No Data
BJDX Bluejay Diagnostics	9	4.47 million	4.20 million	Not Optionable
INM InMed Pharmaceuticals	10	3.31 million	3.29 million	Not Optionable
LIMN Liminatus Pharma	N/A	1.01 million	816,000	N/A

AXLA, INM, LIMN, and BJDX Headlines

Recent News About These Companies

Liminatus Partners with Korean Firm for CAR-T Study

August 24, 2026 | ocbj.comO

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

August 24, 2026 | globenewswire.com

Liminatus Pharma (NASDAQ:LIMN) Rating Lowered to Strong Sell at Wall Street Zen

August 22, 2026 | americanbankingnews.com

Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock

August 18, 2026 | globenewswire.com

Liminatus Pharma Inc (LIMN)

August 14, 2026 | investing.com

Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement

August 13, 2026 | globenewswire.com

LIMN Share News Today

July 6, 2026 | uk.investing.com

Liminatus Pharma Inc.: Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline

July 1, 2026 | finanznachrichten.de

Liminatus Pharma Inc. - Ordinary Shares - Class A

July 1, 2026 | money.usnews.com

Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline

June 30, 2026 | globenewswire.com

LIMN Liminatus Pharma, Inc.

June 16, 2026 | seekingalpha.com

Liminatus Pharma secures $1.9M cash via warrant exercises

June 3, 2026 | msn.com

Liminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross Proceeds

June 3, 2026 | globenewswire.com

Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy Pipeline

May 22, 2026 | theglobeandmail.com

Liminatus Pharma (LIMN) Stock: Nasdaq Delisting Warning Sparks Volatile Trading Session

May 22, 2026 | blockonomi.com

Liminatus Pharma is trending overnight — here's why LIMN stock surged over 79% in after-hours session

May 22, 2026 | msn.com

Liminatus Pharma Announces Nasdaq Delisting Notification

May 21, 2026 | globenewswire.com

Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session

May 21, 2026 | benzinga.com

Liminatus Pharma, Inc. Class A

March 31, 2026 | edition.cnn.com

Liminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking Antibody

March 17, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AXLA, INM, LIMN, and BJDX Company Descriptions

Axcella Health NASDAQ:AXLA

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Bluejay Diagnostics NASDAQ:BJDX

$0.90 -0.01 (-1.04%)

As of 08/28/2026 04:00 PM Eastern

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

InMed Pharmaceuticals NASDAQ:INM

$1.38 -0.05 (-3.50%)

As of 08/28/2026 04:00 PM Eastern

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Liminatus Pharma NASDAQ:LIMN

$4.23 -0.17 (-3.86%)

As of 08/28/2026 04:00 PM Eastern

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AXLA, INM, LIMN, and BJDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AXLA, INM, LIMN, and BJDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AXLA, INM, LIMN, and BJDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AXLA, INM, LIMN, and BJDX Company Descriptions

Axcella Health NASDAQ:AXLA

Bluejay Diagnostics NASDAQ:BJDX

InMed Pharmaceuticals NASDAQ:INM

Liminatus Pharma NASDAQ:LIMN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AXLA, INM, LIMN, and BJDX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AXLA, INM, LIMN, and BJDX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AXLA, INM, LIMN, and BJDX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AXLA, INM, LIMN, and BJDX Company Descriptions

Axcella Health NASDAQ:AXLA

Bluejay Diagnostics NASDAQ:BJDX

InMed Pharmaceuticals NASDAQ:INM

Liminatus Pharma NASDAQ:LIMN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools